Albuminuria: a vital sign of kidney health in contemporary clinical practice

Q: What is the clinical evidence from this study?

Study design: Review. Population: Chronic Kidney Disease. Intervention: Urinary albumin-to-creatinine ratio (UACR) testing.

Q: What does this research mean for the field?

Urinary albumin-to-creatinine ratio complements estimated glomerular filtration rate by enabling earlier detection of chronic kidney disease, providing independent cardiorenal prognostic risk assessment, and guiding disease-modifying therapies in primary care. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Răzvan-Florentin Miftode

doi:10.26416/med.172.4.2026.11745

January 1, 2026Medic roOpen Access

Albuminuria: a vital sign of kidney health in contemporary clinical practice

View Full Paper

Ask AI

Bookmark

Share

Key result

Systematic integration of urinary albumin-to-creatinine ratio testing in at-risk patients enables earlier identification of chronic kidney disease and guides disease-modifying therapies to improve cardiorenal outcomes.

Why the study?

Albuminuria is a key marker of kidney injury and cardiorenal risk, but its role in detection, risk stratification, and management of CKD in primary care requires summarization and integration with recent guidelines and studies.

Key Points

To summarize the role of the urinary albumin-to-creatinine ratio (UACR) in the detection, risk stratification, and management of chronic kidney disease (CKD), with an emphasis on primary care.
Synthesized clinical practice guidance from KDIGO 2024, ESC 2024, and ADA 2026 alongside recent clinical studies and analyses.
Assessed diagnostic workflows, biological variability considerations, spot urine sampling protocols, and joint interpretation frameworks alongside eGFR.
Persistent albuminuria with UACR ≥30 mg/g confirms kidney damage and establishes a diagnosis of CKD even when eGFR remains ≥60 mL/min/1,73 m², provided persistence is documented for at least three months.
Albuminuria is stratified into three KDIGO prognostic stages: normal or mildly increased (A1, <30 mg/g), moderately increased (A2, 30-299 mg/g), and severely increased (A3, ≥300 mg/g).
Routine UACR testing enables timely initiation of disease-modifying therapies, including renin-angiotensin system blockade, SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists.

Structured PICO

P

Population

Patients at risk for chronic kidney disease (e.g., diabetes mellitus, hypertension, cardiovascular disease, obesity, older age, or family history of kidney disease) seen in primary care

I

Intervention

Routine assessment of urinary albumin-to-creatinine ratio (UACR) combined with estimated glomerular filtration rate (eGFR) and implementation of disease-modifying therapies (renin-angiotensin system blockade, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists)

Limitations

Albuminuria testing remains underutilized in clinical practice despite guideline recommendations.
Barriers in primary care include the perception that the test is not a priority, unclear responsibility between specialties, poor integration into practice workflow, and difficulties tracking results.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Systematic integration of UACR testing alongside eGFR in at-risk patients is essential for early chronic kidney disease detection, cardiorenal risk stratification, and guiding guideline-directed medical therapy in everyday clinical care.

Abstract

Albuminuria is an accessible marker of kidney injury and a major determinant of cardiorenal risk. This paper summarizes the role of the urinary albumin-to-creatinine ratio (UACR) in the detection, risk stratification and management of chronic kidney disease (CKD), with emphasis on primary care. Recommendations from KDIGO 2024, ESC 2024 and ADA 2026 were integrated with recent relevant clinical studies and analyses. UACR complements estimated glomerular filtration rate, enables earlier identification of CKD and provides independent renal and cardiovascular prognostic information. Confirmation of persistent albuminuria and joint interpretation with eGFR are essential. Contemporary disease-modifying therapies – renin-angiotensin system blockade, SGLT2 inhibitors, finerenone and, in selected patients, GLP-1 receptor agonists – can improve outcomes. Systematic integration of UACR testing in people at risk may turn albuminuria into a practical renal vital sign in everyday clinical care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Răzvan-Florentin Miftode (2026) conducted a review in Chronic Kidney Disease. Urinary albumin-to-creatinine ratio (UACR) testing was evaluated. Systematic integration of urinary albumin-to-creatinine ratio testing in at-risk patients enables earlier identification of chronic kidney disease and guides disease-modifying therapies to improve cardiorenal outcomes.

synapsesocial.com/papers/6ad75065437c59c3d858a3e4 https://doi.org/10.26416/med.172.4.2026.11745

View Full Paper

Ask AI

Bookmark

Share

Albuminuria: a vital sign of kidney health in contemporary clinical practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Albuminuria: a vital sign of kidney health in contemporary clinical practice

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading